Learning from the youngsters: ixekizumab in active ankylosing spondylitis

被引：4

作者：

Baraliakos, Xenofon ^{[1
]}

Braun, Juergen ^{[1
]}

机构：

[1] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet Herne, D-44649 Herne, Germany

来源：

LANCET | 2018年 / 392卷 / 10163期

关键词：

AXIAL SPONDYLOARTHRITIS; SECUKINUMAB; CRITERIA;

D O I：

10.1016/S0140-6736(18)32340-7

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

引用

页码：2415 / 2416

页数：2

共 11 条

[1]

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis [J].

Baeten, Dominique ;

Sieper, Joachim ;

Braun, Juergen ;

Baraliakos, Xenofon ;

Dougados, Maxime ;

Emery, Paul ;

Deodhar, Atul ;

Porter, Brian ;

Martin, Ruvie ;

Andersson, Mats ;

Mpofu, Shephard ;

Richards, Hanno B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (26) :2534-2548

[2]

Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis [J].

Baraliakos, Xenofon ;

Haibel, Hildrun ;

Listing, Joachim ;

Sieper, Joachim ;

Braun, Juergen .

ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (04) :710-715

[3]

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study [J].

Braun, Juergen ;

Baraliakos, Xenofon ;

Deodhar, Atul ;

Baeten, Dominique ;

Sieper, Joachim ;

Emery, Paul ;

Readie, Aimee ;

Martin, Ruvie ;

Mpofu, Shephard ;

Richards, Hanno B. .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (06) :1070-1077

[4]

The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis [J].

Deodhar, Atul ;

Strand, Vibeke ;

Kay, Jonathan ;

Braun, Juergen .

ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (05) :791-794

[5]

Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study [J].

Kivitz, Alan J. ;

Wagner, Ulf ;

Dokoupilova, Eva ;

Supronik, Jerzy ;

Martin, Ruvie ;

Talloczy, Zsolt ;

Richards, Hanno B. ;

Porter, Brian .

RHEUMATOLOGY AND THERAPY, 2018, 5 (02) :447-462

[6]

Liu L, 2016, J INFLAMM RES, V9, P39, DOI [10.3993/jfbim00203, 10.2147/JIR.S100940]

[7]

Emerging drugs for the treatment of axial spondyloarthritis [J].

Rademacher, Judith ;

Poddubnyy, Denis .

EXPERT OPINION ON EMERGING DRUGS, 2018, 23 (01) :83-96

[8]

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection [J].

Rudwaleit, M. ;

van der Heijde, D. ;

Landewe, R. ;

Listing, J. ;

Akkoc, N. ;

Brandt, J. ;

Braun, J. ;

Chou, C. T. ;

Collantes-Estevez, E. ;

Dougados, M. ;

Huang, F. ;

Gu, J. ;

Khan, M. A. ;

Kirazli, Y. ;

Maksymowych, W. P. ;

Mielants, H. ;

Sorensen, I. J. ;

Ozgocmen, S. ;

Roussou, E. ;

Valle-Onate, R. ;

Weber, U. ;

Wei, J. ;

Sieper, J. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (06) :777-783

[9]

New evidence on the management of spondyloarthritis [J].

Sieper, Joachim ;

Poddubnyy, Denis .

NATURE REVIEWS RHEUMATOLOGY, 2016, 12 (05) :282-295

[10]

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial [J].

van der Heijde, Desiree ;

Wei, James Cheng-Chung ;

Dougados, Maxime ;

Mease, Philip ;

Deodhar, Atul ;

Maksymowych, Walter P. ;

Van den Bosch, Filip ;

Sieper, Joachim ;

Tomita, Tetsuya ;

Landewe, Robert ;

Zhao, Fangyi ;

Krishnan, Eswar ;

Adams, David H. ;

Pangallo, Beth ;

Carlier, Hilde .

LANCET, 2018, 392 (10163) :2441-2451

← 1 2 →